ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1552	National Cancer Institute	Html	en	Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version	Childhood ALL is a type of cancer in which the bone marrow makes too many immature lymphocytes (a type of white blood cell). Here’s what you need to know about the risk factors, signs, tests to diagnose, and treatment of newly diagnosed and recurrent ALL in this expert-reviewed summary.	red blood cells 0.416225 cancer treatment 0.28631 chemotherapy 0.431874 treatments 0.247489 PDQ cancer information 0.278302 clinical trial search 0.311111 white blood cells 0.50903 children 0.34365 systemic chemotherapy 0.367092 higher doses 0.258659 mature blood cells 0.277223 Natural killer cells 0.232346 cancer information summary 0.242631 clinical trial 0.414978 stem cells 0.325781 stem cell transplant 0.490178 Lymphoblastic Leukemia Treatment 0.242048 blood cells 0.556083 intrathecal chemotherapy 0.289545 radiation therapy 0.442509 General information 0.218828 child 0.225345 treatment 0.73359 immature blood cells 0.228445 NCI-supported cancer 0.228604	cancer cells 0.364563 remission induction 0.378898 anticancer drugs 0.454791 specific cancer cells 0.244448 acute lymphocytic leukemia 0.228943 certain changes 0.25566 treatment clinical trials 0.245143 blood stem cells 0.262182 National Cancer Institute 0.245665 spinal cord 0.639894 ) cells. 0.915202 new treatment 0.267478 consolidation /intensification 0.293759 childhood 0.307766 clinical trials 0.932686 combination chemotherapy 0.358378 maintenance phases 0.246634 brain 0.275475 bone marrow 0.619374 Philadelphia chromosome 0.248781 cancer clinical trials 0.319159 acute lymphoblastic leukemia 0.930995 cancer 0.710977 information 0.309067	CLICK HERE
1653	National Cancer Institute	Html	en	Cancer Genetics Overview (PDQ®)–Health Professional Version	Expert-reviewed information summary in which the features of hereditary cancer and the structure and content of other PDQ cancer genetics summaries are described. The summary also contains an extensive list of genetics resources available online.	risk assessment 0.737084 germline genetic testing 0.616915 pathogenic germline variants 0.607786 genetics cancer risk 0.586595 germline testing 0.54014 individual PDQ summaries 0.545357 common genetic variants 0.594544 Founder pathogenic variants 0.555775 Cancer Genetics Risk 0.634713 tumor sequencing 0.540563 cancer risk counseling 0.587676 genetic risk 0.584149 health care providers 0.553143 genetic risk assessment 0.574763 family members 0.586643 pathogenic variant 0.712171 cancer predisposition genes 0.581734 cancer risk assessment 0.656292 BRCA1/BRCA2 pathogenic variants 0.580746 rare genetic variants 0.585466 familial cancer risk 0.606217 germline pathogenic variant 0.590911 specific pathogenic variant 0.581389 genetic cancer susceptibility 0.617626 genetic sequence testing 0.55336	breast cancer panel 0.575181 genetic counseling 0.75599 certain pathogenic variants 0.569596 cancer susceptibility genes 0.662603 multigene testing 0.554102 pathogenic variants 0.772898 term pathogenic variant 0.577821 genetic information 0.615701 predisposition genetic testing 0.569525 health care 0.629277 actionable genetic variants 0.56222 cancer susceptibility 0.729483 multigene tests 0.585492 Cancer genetic counseling 0.65952 breast cancer 0.623534 cancer predisposition multigene 0.547293 cancer susceptibility gene 0.552935 well-characterized cancer susceptibility 0.539905 genetic variants 0.628939 prostate cancer 0.563348 genetic testing 0.723596 family history 0.559221 cancer risk 0.746235 cancer 0.908258	CLICK HERE
1908	National Cancer Institute	Html	es	Tratamiento de la leucemia mieloide aguda en adultos (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mieloide aguda en adultos.	linfocítica aguda 0.505572 leucemia promielocítica aguda 0.536157 siguientes procedimientos 0.505247 células madre 0.703397 leucemia mielógena aguda 0.512482 posibles factores 0.501447 siguientes aspectos 0.5019 leucemia aguda 0.511873 radiación quizás 0.505162 leucemia linfoblástica aguda 0.535526 LMA quizás 0.505703 hueso compacto 0.505434 neoplasias mieloides 0.501631 rayos x 0.501258 enlace drugs approved 0.505977 Acute Myeloid Leukemia 0.506164 célula madre mieloide 0.516071 cáncer.ampliar aspiración 0.501565 líquido cefalorraquídeo 0.511938	punción espinal.Ampliar 0.501523 National Cancer Institute 0.501258 leucemia granulocítica aguda 0.512402 Instituto Nacional 0.502137 célula madre linfoide 0.510737 PDQ Tratamiento 0.503456 sustancia química benceno 0.502803 leucemia mielógena 0.513696 médula espinal.ampliar quimioterapia 0.50588 leucemia mieloblástica aguda 0.512403 sistema nervioso central 0.50789 Physician Data Query 0.504454 madre mieloides 0.518606 siguientes situaciones 0.504197 células madre mieloides 0.508803 leucemia mieloide aguda 0.995372 célula madre 0.532153 blastocito mieloide 0.505386 siguientes sumarios 0.503116	CLICK HERE
2987	National Cancer Institute	Html	en	Secondhand Smoke	When you smoke, it doesn't just affect you. And it's not just irritating to those around you, it's deadly.	feet 0.409991 dangers 0.420271 Lung cancer 0.428942 good example 0.428021 non-smoker 0.407426 care staff 0.426607 nicotine affect 0.427281 babysitters 0.406286 body 0.411562 smoker 0.414092 children 0.431937 harms 0.407652 sure caretakers 0.428123 secondhand smoke 0.971613 non-smokers 0.43912 heart disease‚ 0.429635 Fact 0.410452 short time 0.429909 somebody 0.406088 health problems 0.428728 smokefree restaurants 0.432863 lung infections 0.428228 smoking indoors 0.445671 main way smoking 0.477206 Breathing problems 0.428866	indoor public places 0.450365 babies 0.424287 smokers 0.419121 air 0.417572 life 0.412446 Breathing secondhand smoke 0.5983 infant death syndrome 0.453829 smoking 0.508887 National Cancer Institute 0.448359 heart attack‚ 0.429618 kids 0.411336 quiz 0.411311 cigarette 0.405834 coughing‚ extra phlegm‚ 0.454984 bronchitis 0.405901 people 0.432125 home 0.416331 nannies 0.405803 severe attacks 0.428972 best thing 0.428251 shortness 0.406847 ear infections 0.428442 low birth weight 0.454001 family 0.425482	CLICK HERE
3416	National Cancer Institute	Html	en	The NCTN Budget	The overall NCTN budget for these awards is $151 million. This amount is the same as the total budget provided to the Cooperative Groups for awards in each of fiscal years 2012 and 2013, despite the substantial reductions in the NCI budget that resulted from sequestration starting in 2013. What has changed, however, is the distribution of funds to the various components of the NCTN, as compared with the components of the former Cooperative Group program.	future clinical trials 0.56818 large numbers 0.48775 medicine clinical trials 0.552592 Medidata Rave® 0.477945 smaller interventional components 0.50085 NCI budget 0.524673 complex analytic algorithms 0.469817 important trials 0.467438 clinical trial functions 0.476947 additional annual support 0.477353 entail new expenses 0.505576 clinical trials 0.953052 funding supplements 0.459855 one-stop online access 0.458554 Group Operations Center 0.520009 normal genetic variants 0.470288 overall NCTN budget 0.558633 patients 0.498402 separate funding stream 0.466002 Network Group Operations 0.667965 Investigational New Drug 0.483971 NCTN treatment trials 0.641251 fresh biopsy samples 0.473644 Studies Funding Program 0.482252 Group Operations Centers 0.508084	NCI 0.653194 patient selection 0.483879 U.S. adult groups 0.497468 appropriate molecular profile 0.474342 Cooperative Groups 0.505409 RNA sequencing methods 0.473512 Cancer Trials Support 0.534613 NCTN trials 0.601972 actual interventional study 0.491932 specific molecular characteristics 0.475625 fewer active trials 0.544364 rapid turnaround times 0.471955 NCTN groups 0.757227 NCTN Group Operations 0.525903 separate NCI award 0.549229 interventional trials 0.493629 newly consolidated groups 0.490605 Cooperative Group program 0.522132 larger therapeutic effects 0.463659 correlative science studies 0.465254 common data management 0.623125 new trials 0.510263 group trials 0.461981 previous trials 0.464198	CLICK HERE
15609	National Cancer Institute	Html	es	Tratamiento de los tumores vasculares infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores vasculares infantiles.	problemas pasajeros 0.409161 lesiones benignas 0.409862 piel vecina 0.430821 efectos secundarios meses 0.423036 importantes preguntas 0.409508 siguientes especialistas 0.418218 siguientes síndromes 0.413185 rayos x 0.412063 niño ayuda 0.413721 escamas llamadas placas 0.409897 tumores benignos 0.516528 tumor vascular benigno 0.534618 Instituto Nacional 0.412348 alta potencia 0.411312 células llamadas 0.410367 tumores vasculares benignos 0.9178 venas sanas vecinas 0.421159 nuevos tipos 0.412108 sangre circula 0.414383 medicamentos propranolol hydrochloride 0.437459 angiofibroma nasofaríngeo 0.468048 hemangioendotelioma epitelioides 0.436434 once tipos 0.436191 glándula tiroides 0.427118 posibles efectos tardíos 0.424225	adultos jóvenes 0.418525 siguientes tumores 0.604051 granulomas piógenos 0.445724 hemangioma capilar lobulillar 0.505924 siguientes tipos 0.41901 ondas sonoras 0.412577 efectos tardíos 0.50862 PDQ Efectos tardíos 0.43716 vías respiratorias 0.428225 tarde.ampliar ecografía 0.413763 granuloma piógeno 0.509033 IRMN).Ampliar Imágenes 0.410245 sección opciones 0.41178 hemangioendoteliomas epitelioides 0.418326 PDQ Tratamiento 0.421361 afección llamada esclerosis 0.414532 siguientes signos 0.417619 siguientes casos 0.414811 Physician Data Query 0.425443 propranolol iv 0.42341 insuficiencia cardíaca 0.475544 hemangioma epitelioide 0.568564 siguientes pruebas 0.434586 angiofibromas nasofaríngeos juveniles 0.440153	CLICK HERE
16681	National Cancer Institute	Html	en	Cancer Moonshot℠ Blue Ribbon Panel Members	Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science.	Walton Endowed Chair 0.567818 Cancer Genome Computational 0.597352 National Cancer Advisory 0.650925 cancer advocacy groups 0.631303 Integrative Cancer Research 0.659981 Cancer Disparities Program 0.610947 C. Zamecnik Chair 0.57469 Senior Vice President 0.528963 Harvard Medical School 0.539573 Chief Executive Officer 0.838453 Moores Cancer Center 0.633784 Cancer Center 0.989395 Principal Deputy Director 0.559096 Kimmel Cancer Center 0.636717 MGH Cancer Center 0.643509 Associate Professor 0.561481 Texas MD Anderson 0.619653 Scott Cancer Center 0.628322 Hopkins University School 0.586476 Lurie Comprehensive Cancer 0.604578 National Brain Tumor 0.535602 Alumni Distinguished Professor 0.55884 cancer health disparities 0.665713 Thomas Jefferson University 0.541957 cancer prevention 0.57231	Lineberger Comprehensive Cancer 0.60209 Huntsman Cancer Institute 0.643082 Ph.D 0.602332 Anderson Cancer Center 0.720144 Dana-Farber Cancer Institute 0.630726 Louisiana State University 0.545794 Pfizer Worldwide Research 0.555824 National Cancer Institute 0.714187 Cancer Research 0.712054 Sidney Kimmel 0.530896 Hospital Cancer Center 0.648303 Blue Ribbon Panel 0.726957 M.D 0.540388 Executive Vice President 0.545293 MD Anderson Cancer 0.692003 Ludwig Cancer Research 0.634757 Clinical Cancer Care 0.584227 Comprehensive Cancer Center 0.832766 Clausen Distinguished Professor 0.578861 Cancer Survivorship 0.543835 Kimmel Comprehensive Cancer 0.643464 Vanderbilt-Ingram Cancer Center 0.63051 University Feinberg School 0.566744 Deputy Director 0.630447	CLICK HERE
16775	National Cancer Institute	Html	es	Cancell/Cantron/Protocel (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de Cancell/Entelev como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Centro Nacional 0.429084 New Hampshire Avenue 0.419912 cabo ensayos 0.419001 Drug Administration 0.412413 NCI Best Case 0.439351 tipo cancell 0.440349 mejores pruebas 0.415762 datos bibliográficos pubmed 0.42161 siguientes preguntas 0.412513 James V 0.418429 National Cancer Institute 0.425345 siguientes riesgos 0.416342 seguro médico 0.411884 Instituto Nacional 0.685274 vitamina e 0.418575 Salud Complementaria 0.444832	Visuals Online 0.415001 complementarias revisa 0.421711 Physician Data Query 0.488672 nombre cancell 0.440323 Estados Unidos 0.994944 libre uso 0.416016 suficiente actividad 0.418205 siguientes sustancias 0.422749 página manejo 0.413947 ¿El tratamiento 0.424367 ¿Los beneficios 0.412704 juntos cam 0.411781 Series Program 0.412549 medicina complementaria 0.882014 Institutos Nacionales 0.47694	CLICK HERE
16841	National Cancer Institute	Html	en	Nanotechnology Characterization Laboratory (NCL)	The Nanotechnology Characterization Laboratory (NCL) is accelerating the development of promising nanotechnology therapies and diagnostics.	extensive educational outreach 0.634447 FDA 0.244496 Nanotechnology Characterization Laboratory 0.767048 oncology-directed therapies 0.46705 great strides 0.507003 pursuit 0.246467 death rate 0.462099 Drug Administration 0.456372 unique setup 0.432854 progression 0.249487 concert 0.241265 effort 0.242009 extraordinary opportunity 0.441323 dozen NCL collaborators 0.920466 disadvantages 0.25207 relatively limited time 0.630205 biocompatibility trends 0.467853 National Cancer Institute 0.664151 National Institute 0.449153 Food 0.241207	human clinical trials 0.632541 development 0.239992 clinical translation 0.459921 therapeutic outcomes 0.469235 diagnosis 0.245742 difficult diseases 0.491415 diagnostic capabilities 0.458058 novel nanomedicines 0.45591 vast array 0.436858 different nanomaterials 0.457741 Standards 0.240975 population 0.239972 diagnostics 0.244317 advantages 0.242363 cancers 0.321573 foremost nanotechnology research 0.719052 preclinical characterization 0.513184 novel treatment strategies 0.62837 incidence 0.254427 multi-disciplinary team 0.450189	CLICK HERE
17193	National Cancer Institute	Html	en	U.S. - China Program for Biomedical Research Cooperation	U.S. - China Program for Biomedical Research Cooperation Preliminary Program Review.	Office 0.440565 OAR 0.472714 Allergy 0.446266 scientific accomplishments 0.62865 projects 0.51324 Additional outcomes 0.632018 National Natural Science 0.9169 Mental Health 0.663295 Chinese scientists 0.664312 translational biomedical research. 0.976759 National Cancer Institute 0.919012 Foundation 0.442112 preliminary evaluation 0.675445 US-China 0.436834 results 0.435543 National Institute 0.932171 National Institutes 0.697264 common successes 0.636736 Administrative Supplements 0.654736 Stroke 0.440417 Collaborative Biomedical Research 0.935063	Global Health 0.637782 NSFC 0.441999 future collaborative programs 0.854353 impacts 0.442029 countries 0.439905 NIAID 0.482086 NIH 0.458074 international collaboration 0.640713 joint initiative 0.663479 Neurological Disorders 0.660677 NIMH 0.468305 Researchers 0.441544 U.S.-China Program 0.677605 report 0.435896 Infectious Diseases 0.665033 scientifically meritorious investigations 0.921915 Biomedical Research Cooperation 0.865108 Preliminary Program Review 0.859879 AIDS Research 0.660227 R01 mechanisms 0.711872	CLICK HERE